Rdif
- All
- News
- Videos
- Web Stories
-
Mixing AstraZeneca, Sputnik Shows "No Serious Adverse Effects": Report
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces initial safety results of the world's first study of a combination between the AstraZeneca vaccine and the first component of the Sputnik V vaccine.
-
Vietnam Produces Test Batch Of Sputnik V Vaccine: Russia
Russia announced Wednesday that a batch of its Sputnik V coronavirus vaccine was produced for the first time in Vietnam, which is battling a new wave of COVID-19 infections.
-
Russia's Sputnik V Vaccine Effective Against Delta, Other Covid Variants: Study
The Gamaleya National Research Center of Epidemiology and Microbiology and RDIF on Monday announced strong results of the study on neutralizing the activity of sera from individuals vaccinated with Sputnik V vaccine against new coronavirus variants.
-
Morepen Labs In Himachal Starts Production Of Test Batch Of Sputnik V Vaccine
Morepen Laboratories has started production of the test batch of Russia's Sputnik V COVID-19 vaccine at its facility in Himachal Pradesh, Russian Direct Investment Fund (RDIF) and the domestic drug firm said in a statement on Tuesday.
-
Sputnik Light Covid Vaccine Shows 78.6-83.7% Efficacy Among Elderly: Russian Maker
The Russian Direct Investment Fund (RDIF) on Wednesday announced that the Russian Sputnik Light coronavirus vaccine demonstrates 78.6-83.7 per cent efficacy among the elderly.
-
Mumbai Gets 3 Bids From Russia's Sputnik Covid Vaccine Makers
The London-based facilitator of the Russian Direct Investment Fund and its India-based independent representatives have together made three bids for the supply of one crore Sputnik V Covid vaccine doses to the Mumbai civic body.
-
Sputnik More Effective Against Mutations, Says Russian Maker. Here's Why
Russia's Sputnik V, the third Covid vaccine to be cleared for use in India, is effective against mutant strains, the Russian Direct Investment Fund (RDIF) has said.
-
India's Panacea Biotec To Make 100 Million Sputnik Vaccine Doses Yearly: Report
Indian biotech firm Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct Investment Fund (RDIF), which markets the shot internationally, said on Monday.
-
Hyderabad-Based Virchow Biotech To Produce Sputnik V Vaccine In India
Russian Direct Investment Fund (RDIF) and Hyderabad-based Virchow Biotech on Monday announced an agreement to produce up to 200 million doses of Sputnik V vaccine in India.
-
India's Gland Pharma To Produce Up To 252 Million Doses For Russia's Sputnik V Vaccine
India's Gland Pharma Ltd said on Tuesday it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce and supply up to 252 million doses of the Sputnik V COVID-19 vaccine.
-
Gland Pharma Rallies On Agreement To Produce Sputnik V Covid-19 Vaccine
Gland Pharma has entered into an agreement to produce and supply 252 million doses of RDIF Sputnik V COVID-19 vaccine.
-
Russia Expects India To Approve Sputnik V Vaccine For Use Soon: Report
India is expected to grant emergency use authorization for Russia's Sputnik V COVID-19 vaccine this month or next, the Russian Direct Investment Fund (RDIF), which markets the shot abroad, told ANI on Tuesday.
-
Russian Covid Vaccine In Phase 3 Trial, To Cost Less Than $10 Per Dose In India
The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.
-
Dr Reddy's Labs Commences Clinical Trials Of Sputnik V Vaccine; Stock Gains 1%
In September 2020, Dr. Reddy's and RDIF had entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
-
Dr Reddy's, Russian Firm RDIF Begin Clinical Trials For Covid Vaccine Sputnik V In India
Dr Reddy's Laboratories and the Russian Direct Investment Fund (RDIF) on Tuesday announced the start of adaptive phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving necessary clearance from the Central Drugs Laboratory in Himachal Pradesh.
-
Mixing AstraZeneca, Sputnik Shows "No Serious Adverse Effects": Report
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces initial safety results of the world's first study of a combination between the AstraZeneca vaccine and the first component of the Sputnik V vaccine.
-
Vietnam Produces Test Batch Of Sputnik V Vaccine: Russia
Russia announced Wednesday that a batch of its Sputnik V coronavirus vaccine was produced for the first time in Vietnam, which is battling a new wave of COVID-19 infections.
-
Russia's Sputnik V Vaccine Effective Against Delta, Other Covid Variants: Study
The Gamaleya National Research Center of Epidemiology and Microbiology and RDIF on Monday announced strong results of the study on neutralizing the activity of sera from individuals vaccinated with Sputnik V vaccine against new coronavirus variants.
-
Morepen Labs In Himachal Starts Production Of Test Batch Of Sputnik V Vaccine
Morepen Laboratories has started production of the test batch of Russia's Sputnik V COVID-19 vaccine at its facility in Himachal Pradesh, Russian Direct Investment Fund (RDIF) and the domestic drug firm said in a statement on Tuesday.
-
Sputnik Light Covid Vaccine Shows 78.6-83.7% Efficacy Among Elderly: Russian Maker
The Russian Direct Investment Fund (RDIF) on Wednesday announced that the Russian Sputnik Light coronavirus vaccine demonstrates 78.6-83.7 per cent efficacy among the elderly.
-
Mumbai Gets 3 Bids From Russia's Sputnik Covid Vaccine Makers
The London-based facilitator of the Russian Direct Investment Fund and its India-based independent representatives have together made three bids for the supply of one crore Sputnik V Covid vaccine doses to the Mumbai civic body.
-
Sputnik More Effective Against Mutations, Says Russian Maker. Here's Why
Russia's Sputnik V, the third Covid vaccine to be cleared for use in India, is effective against mutant strains, the Russian Direct Investment Fund (RDIF) has said.
-
India's Panacea Biotec To Make 100 Million Sputnik Vaccine Doses Yearly: Report
Indian biotech firm Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct Investment Fund (RDIF), which markets the shot internationally, said on Monday.
-
Hyderabad-Based Virchow Biotech To Produce Sputnik V Vaccine In India
Russian Direct Investment Fund (RDIF) and Hyderabad-based Virchow Biotech on Monday announced an agreement to produce up to 200 million doses of Sputnik V vaccine in India.
-
India's Gland Pharma To Produce Up To 252 Million Doses For Russia's Sputnik V Vaccine
India's Gland Pharma Ltd said on Tuesday it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce and supply up to 252 million doses of the Sputnik V COVID-19 vaccine.
-
Gland Pharma Rallies On Agreement To Produce Sputnik V Covid-19 Vaccine
Gland Pharma has entered into an agreement to produce and supply 252 million doses of RDIF Sputnik V COVID-19 vaccine.
-
Russia Expects India To Approve Sputnik V Vaccine For Use Soon: Report
India is expected to grant emergency use authorization for Russia's Sputnik V COVID-19 vaccine this month or next, the Russian Direct Investment Fund (RDIF), which markets the shot abroad, told ANI on Tuesday.
-
Russian Covid Vaccine In Phase 3 Trial, To Cost Less Than $10 Per Dose In India
The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.
-
Dr Reddy's Labs Commences Clinical Trials Of Sputnik V Vaccine; Stock Gains 1%
In September 2020, Dr. Reddy's and RDIF had entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
-
Dr Reddy's, Russian Firm RDIF Begin Clinical Trials For Covid Vaccine Sputnik V In India
Dr Reddy's Laboratories and the Russian Direct Investment Fund (RDIF) on Tuesday announced the start of adaptive phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving necessary clearance from the Central Drugs Laboratory in Himachal Pradesh.
